|
1
|
Mirantes C, Espinosa I, Ferrer I, Dolcet
X, Prat J and Matias-Guiu X: Epithelial-to-mesenchymal transition
and stem cells in endometrial cancer. Hum Pathol. 44:1973–1981.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wojciechowska U and Didkowska J: Cancer in
Poland in 2010. Nowotwory. 63:197–216. 2013.
|
|
3
|
Bray F, Dos Santos Silva I, Moller H and
Weiderpass E: Endometrial cancer incidence trends in Europe:
underlying determinants and prospects for prevention. Cancer
Epidemiol Biomarkers Prev. 14:1132–1142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Horn LC, Meinel A, Handzel R and Einenkel
J: Histopathology of endometrial hyperplasia and endometrial
carcinoma: an update. Ann Diagn Pathol. 11:297–311. 2007.
View Article : Google Scholar
|
|
6
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Randall TC and Kurman RJ: Progestin
treatment of atypical hyperplasia and well-differentiated carcinoma
of the endometrium in women under age 40. Obstet Gynecol.
90:434–440. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sherman ME, Sturgeon S, Brinton LA, et al:
Risk factors and hormone levels in patients with serous and
endometrioid uterine carcinomas. Mod Pathol. 10:963–968.
1997.PubMed/NCBI
|
|
9
|
Ayhan A, Gultekin M and Dursun P: Textbook
of Gynaecological Oncology. Günes Publishing; Ankara: 2010
|
|
10
|
Yeramian A, Moreno-Bueno G, Dolcet X, et
al: Endometrial carcinoma: molecular alterations involved in tumor
development and progression. Oncogene. 32:403–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Busmanis I, Ho TH, Tan SB and Khoo KS: p53
and bcl-2 expression in invasive and pre-invasive uterine papillary
serous carcinoma and atrophic endometrium. Ann Acad Med Singapore.
34:421–425. 2005.PubMed/NCBI
|
|
12
|
Caduff RF, Johnston CM and Frank TS:
Mutations of the Ki-ras oncogene in carcinoma of the endometrium.
Am J Pathol. 146:182–188. 1995.PubMed/NCBI
|
|
13
|
Mutter GL, Lin MC, Fitzgerald JT, et al:
Altered PTEN expression as a diagnostic marker for the earliest
endometrial precancers. J Natl Cancer Inst. 92:924–930. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mutter GL, Boynton KA, Faquin WC, Ruiz RE
and Jovanovic AS: Allelotype mapping of unstable microsatellites
establishes direct lineage continuity between endometrial
precancers and cancer. Cancer Res. 56:4483–4486. 1996.
|
|
15
|
Strissel PL, Ellmann S, Loprich E, et al:
Early aberrant insulin-like growth factor signaling in the
progression to endometrial carcinoma is augmented by tamoxifen. Int
J Cancer. 123:2871–2879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rose PG: Endometrial carcinoma. N Engl J
Med. 335:640–649. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Onuma K, Dabbs DJ and Bhargava R:
Mammaglobin expression in the female genital tract:
immunohistochemical analysis in benign and neoplastic endocervix
and endometrium. Int J Gynecol Pathol. 27:418–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grushko TA, Filiaci VL, Mundt AJ, et al:
An exploratory analysis of HER-2 amplification and overexpression
in advanced endometrial carcinoma: a gynecologic oncology group
study. Gynecol Oncol. 108:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zaczek A, Wełnicka-Jaśkiewicz M, Bielawski
KP, et al: Gene copy numbers of HER family in breast cancer.
J Cancer Res Clin Oncol. 134:271–279. 2008. View Article : Google Scholar
|
|
20
|
Zaczek A, Brandt B and Bielawski KP: The
diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine
kinase receptors and the consequences for therapeutic approaches.
Histol Histopathol. 20:1005–1015. 2005.PubMed/NCBI
|
|
21
|
Salvesen HB, Carter SL, Mannelqvist M, et
al: Integrated genomic profiling of endometrial carcinoma
associates aggressive tumors with indicators of PI3 kinase
activation. Proc Natl Acad Sci USA. 106:4834–4839. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ponzielli R, Katz S, Barsyte-Lovejoy D and
Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J
Cancer. 41:2485–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Semczuk A and Jakowicki JA: Alterations of
pRb1-cyclin D1-cdk4/6-p16INK4A pathway in endometrial
carcinogenesis. Cancer Lett. 203:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsiambas E, Alexopoulou D, Lambropoulou S,
Gerontopoulos K, Karakitsos P and Karameris A: Targeting
topoisomerase IIa in endometrial adenocarcinoma: a combined
chromogenic in situ hybridization and immunohistochemistry study
based on tissue microarrays. Int J Gynecol Cancer. 16:1424–1431.
2006. View Article : Google Scholar
|
|
25
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Consultation WE: Appropriate body-mass
index for Asian populations and its implications for policy and
intervention strategies. Lancet. 363:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jönsson G, Staaf J, Olsson E, et al:
High-resolution genomic profiles of breast cancer cell lines
assessed by tiling BAC array comparative genomic hybridization.
Genes Chromosomes Cancer. 46:543–558. 2007.PubMed/NCBI
|
|
28
|
Vandesompele J, De Preter K, Pattyn F, et
al: Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome
Biol. 3:research00342002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hellemans J, Mortier G, De Paepe A,
Speleman F and Vandesompele J: qBase relative quantification
framework and software for management and automated analysis of
real-time quantitative PCR data. Genome Biol. 8:R192007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McShane LM, Altman DG, Sauerbrei W, et al:
REporting recommendations for tumor MARKer prognostic studies
(REMARK). Nat Clin Pract Oncol. 2:416–422. 2005. View Article : Google Scholar
|
|
31
|
Järvinen TA, Tanner M, Rantanen V, et al:
Amplification and deletion of topoisomerase IIα associate with
ErbB-2 amplification and affect sensitivity to topoisomerase II
inhibitor doxorubicin in breast cancer. Am J Pathol. 156:839–847.
2000.
|
|
32
|
Supernat A, Lapińska-Szumczyk S, Sawicki
S, Wydra D, Biernat W and Zaczek AJ: Deregulation of RAD21
and RUNX1 expression in endometrial cancer. Oncol Lett.
4:727–732. 2012.
|
|
33
|
Inaki K and Liu ET: Structural mutations
in cancer: mechanistic and functional insights. Trends Genet.
28:550–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Watson MA and Fleming TP: Mammaglobin, a
mammary-specific member of the uteroglobin gene family, is
overexpressed in human breast cancer. Cancer Res. 56:860–865.
1996.PubMed/NCBI
|
|
35
|
Classen-Linke I, Moss S, Gröting K, Beier
HM, Alfer J and Krusche CA: Mammaglobin 1: not only a
breast-specific and tumour-specific marker, but also a
hormone-responsive endometrial protein. Histopathology. 61:955–965.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Raeder MB, Birkeland E, Trovik J, et al:
Integrated genomic analysis of the 8q24 amplification in
endometrial cancers identifies ATAD2 as essential to
MYC-dependent cancers. PLoS One. 8:e548732013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Esteller M, García A, Martínez i Palones
JM, Cabero A and Reventós J: Detection of c-erbB-2/neu and
fibroblast growth factor-3/INT-2 but not epidermal growth factor
receptor gene amplification in endometrial cancer by differential
polymerase chain reaction. Cancer. 75:2139–2146. 1995. View Article : Google Scholar
|
|
38
|
Liang H, Cheung LW, Li J, et al:
Whole-exome sequencing combined with functional genomics reveals
novel candidate driver cancer genes in endometrial cancer. Genome
Res. 22:2120–2129. 2012. View Article : Google Scholar
|
|
39
|
Saghir FS, Rose IM, Dali AZ, Shamsuddin Z,
Jamal AR and Mokhtar NM: Gene expression profiling and
cancer-related pathways in type I endometrial carcinoma. Int J
Gynecol Cancer. 20:724–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Konecny GE, Santos L, Winterhoff B, et al:
HER2 gene amplification and EGFR expression in a large cohort of
surgically staged patients with nonendometrioid (type II)
endometrial cancer. Br J Cancer. 100:89–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rolitsky CD, Theil KS, McGaughy VR,
Copeland LJ and Niemann TH: HER-2/neu amplification and
overexpression in endometrial carcinoma. Int J Gynecol Pathol.
18:138–143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsikouras P, Bouchlariotou S, Vrachnis N,
et al: Endometrial cancer: molecular and therapeutic aspects. Eur J
Obstet Gynecol Reprod Biol. 169:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fleming GF, Sill MW, Darcy KM, et al:
Phase II trial of trastuzumab in women with advanced or recurrent,
HER2-positive endometrial carcinoma: a Gynecologic Oncology Group
study. Gynecol Oncol. 116:15–20. 2010. View Article : Google Scholar
|
|
44
|
Santin AD, Bellone S, Roman JJ, McKenney
JK and Pecorelli S: Trastuzumab treatment in patients with advanced
or recurrent endometrial carcinoma overexpressing HER2/neu. Int J
Gynaecol Obstet. 102:128–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Santin AD: Letter to the Editor referring
to the manuscript entitled: ‘Phase II trial of trastuzumab in women
with advanced or recurrent HER-positive endometrial carcinoma: a
Gynecologic Oncology Group study’ recently reported by Fleming et
al, (Gynecol Oncol., 116;15–20;2010). Gynecol Oncol. 118:95–96;
author reply 96–97. 2010.
|
